



Edgar Filing: CorMedix Inc. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01.  
Other  
Events.

On December 10, 2018, CorMedix issued a press release announcing the approval to sell approximately \$5.4 million of NOL tax benefits through the New Jersey Economic Development Authority Program.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.  
Financial  
Statements  
and  
Exhibits.

(d) Exhibits

Exhibit No.	Description
-------------	-------------

<u>99.1</u>	Press release dated December 10, 2018
-------------	---------------------------------------



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: December 10, 2018 By: /s/ Robert W. Cook  
Name Robert W. Cook  
Title Chief Financial Officer